UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000051524
Receipt number R000058779
Scientific Title Randomized controlled trial evaluating the safety and effectiveness of CARTOFINDER guided substrate ablation for non-paroxysmal AF.
Date of disclosure of the study information 2023/07/05
Last modified on 2024/01/05 16:06:35

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A Prospective Randomized Clinical Trial to Validate Atrial Fibrillation Substrate Ablation for Non-Paroxysmal Atrial Fibrillation

Acronym

FINGER AF Trial

Scientific Title

Randomized controlled trial evaluating the safety and effectiveness of CARTOFINDER guided substrate ablation for non-paroxysmal AF.

Scientific Title:Acronym

Randomized controlled FINGER AF trial (FINder Guided sabstratE Radiofrequency catheter ablation for non-pAF)

Region

Japan


Condition

Condition

atrial fibrillation

Classification by specialty

Cardiology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

It was reported that approximately 90% of atrial ectopies trigger atrial fibrillation originate from the myocardium within the pulmonary vein and that catheter ablation of this origin can cure atrial fibrillation. In recent years, pulmonary vein isolation has become the standard of care. However, a second ablation is required in about 50-60% of cases of persistent atrial fibrillation. A number of additional treatment strategies have been proposed to improve outcomes, including ablation of the atrial fibrillation substrate. However, past prospective randomized studies have failed to demonstrate the efficacy of additional ablations that were previously thought to be effective. One factor has been the inadequate assessment of the atrial fibrillation substrate.
Recently, a system (CARTO FINDER) has become available that allows real-time assessment of electrical excitation within the atrium during atrial fibrillation, and is expected to provide high-performance assessment of the atrial fibrillation substrate. However, no randomized, prospective studies have been reported to date demonstrating that additional ablation of the atrial fibrillation substrate outperforms pulmonary vein isolation alone. Prospective, multicenter, randomized trials are needed to establish the evidence.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Atrial fibrillation and tachycardia free rate

Key secondary outcomes

Adverse events related to ablation procedure, heart failure, ischemic stroke, cardiac death


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Device,equipment

Interventions/Control_1

For initial catheter ablation of nonparoxysmal atrial fibrillation, patients will be randomized 1:1 to pulmonary vein isolation alone (Control group) or pulmonary vein isolation plus ablation of the atrial fibrillation substrate as guided by CARTOFINDER.

Interventions/Control_2

For initial catheter ablation of nonparoxysmal atrial fibrillation, patients will be randomized 1:1 to pulmonary vein isolation alone (Control group) or pulmonary vein isolation plus ablation of the atrial fibrillation substrate as guided by CARTOFINDER.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

85 years-old >

Gender

Male and Female

Key inclusion criteria

Patients scheduled for initial catheter ablation for non-paroxysmal atrial fibrillation and who have consented to the study

Key exclusion criteria

Previous cardiac surgery
Patients who are considered unfit for follow-up
NYHA 4th degree heart failure
Atrial fibrillation due to reversible causes
Contraindication to anticoagulation
Pregnancy
Other cases deemed inappropriate by the attending physician

Target sample size

130


Research contact person

Name of lead principal investigator

1st name Naoyuki
Middle name
Last name Miwa

Organization

Tsuchiura Kyodo General Hospital

Division name

Heart Rhythm Center

Zip code

3000028

Address

4-1-1 Ootsuno, Tsuchiura, Ibaraki

TEL

029-830-3711

Email

jet_stream0624@yahoo.co.jp


Public contact

Name of contact person

1st name Naoyuki
Middle name
Last name Miwa

Organization

Tsuchiura Kyodo General Hospital

Division name

Heart Rhythm Center

Zip code

3000028

Address

4-1-1 Ootsuno, Tsuchiura, Ibaraki

TEL

029-830-3711

Homepage URL


Email

jet_stream0624@yahoo.co.jp


Sponsor or person

Institute

Tsuchiura Kyodo General Hospital

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Tsuchiura Kyodo Hospital

Address

4-1-1 Ootsuno, Tsuchiura, Ibaraki

Tel

029-830-3711

Email

jet_stream0624@yahoo.co.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2023 Year 07 Month 05 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2023 Year 07 Month 05 Day

Date of IRB

2022 Year 07 Month 21 Day

Anticipated trial start date

2022 Year 07 Month 22 Day

Last follow-up date

2026 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2023 Year 07 Month 05 Day

Last modified on

2024 Year 01 Month 05 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000058779


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name